USANA Health Sciences, Inc. (NYSE:USNA) has earned an average rating of “Buy” from the seven brokerages that are covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $73.67.

Several research analysts recently weighed in on the company. TheStreet lowered USANA Health Sciences from a “b-” rating to a “c+” rating in a research report on Thursday, July 11th. ValuEngine raised USANA Health Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research raised USANA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $86.00 price target on the stock in a research report on Saturday, October 26th. Jefferies Financial Group assumed coverage on USANA Health Sciences in a research report on Thursday, August 22nd. They set a “hold” rating and a $65.00 price target on the stock. Finally, Pivotal Research reissued a “buy” rating on shares of USANA Health Sciences in a research report on Wednesday, July 24th.

NYSE:USNA opened at $75.28 on Tuesday. The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of 14.59 and a beta of 0.28. USANA Health Sciences has a 1-year low of $58.30 and a 1-year high of $125.61. The business’s fifty day moving average price is $70.90 and its 200 day moving average price is $71.55.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, October 22nd. The company reported $1.09 earnings per share for the quarter, beating the consensus estimate of $0.87 by $0.22. The firm had revenue of $260.60 million for the quarter, compared to analyst estimates of $256.22 million. USANA Health Sciences had a return on equity of 27.60% and a net margin of 9.38%. USANA Health Sciences’s quarterly revenue was down 12.2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.24 earnings per share. As a group, sell-side analysts anticipate that USANA Health Sciences will post 3.99 earnings per share for the current year.

In other USANA Health Sciences news, CFO G Doug Iiekking sold 1,746 shares of the business’s stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $75.33, for a total value of $131,526.18. Following the transaction, the chief financial officer now owns 2,032 shares in the company, valued at $153,070.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Joshua Foukas sold 1,115 shares of the business’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $74.53, for a total value of $83,100.95. The disclosure for this sale can be found here. Insiders have sold 8,385 shares of company stock worth $617,279 over the last three months. 42.50% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of USNA. BlackRock Inc. grew its stake in USANA Health Sciences by 72.6% in the second quarter. BlackRock Inc. now owns 2,302,511 shares of the company’s stock valued at $182,889,000 after purchasing an additional 968,239 shares in the last quarter. Nuveen Asset Management LLC bought a new stake in shares of USANA Health Sciences during the 2nd quarter worth about $17,458,000. Schroder Investment Management Group boosted its stake in shares of USANA Health Sciences by 183.1% during the 2nd quarter. Schroder Investment Management Group now owns 212,492 shares of the company’s stock worth $16,878,000 after acquiring an additional 137,430 shares in the last quarter. Wasatch Advisors Inc. boosted its stake in shares of USANA Health Sciences by 127.0% during the 2nd quarter. Wasatch Advisors Inc. now owns 96,447 shares of the company’s stock worth $7,661,000 after acquiring an additional 53,960 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D bought a new stake in shares of USANA Health Sciences during the 3rd quarter worth about $2,633,000. Hedge funds and other institutional investors own 63.53% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Further Reading: What are defining characteristics of a correction?

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.